The Galatus Foundation
April 21, 2020
July 05, 2020
This study will investigate an antibody which is designed to bind to certain receptors on the surface of neutrophils. Once bound, the drug will block the survival, activation and migration of neutrophils, thereby reducing neutrophil activity, and improving disease outcomes in neutrophil driven inflammation.
Neutrophils are a type of white blood cell that play a key role in the body’s immune response, and are essential for clearing pathogens from the body. However, neutrophils can also negatively contribute to tissue damage in chronic inflammatory diseases. It is therefore imperative that the balance of neutrophils in the body is tightly regulated.
If you are a male or female between the ages of 20-55 you may be eligible for this trial. All participants must be in good general health, and be a non-smoker. In particular, we require Caucasian volunteers, defined as a person who must have any origins in Europe, the Middle East of North Africa. Eligible participants will be reimbursed for their time.
To be eligible you must:
- Healthy male or female
- Weight of between 45 to 63kg
- Aged between 20 and 55 years (inclusive)
- Of white/european origin
- Non-smokers or ex-smokers (who have stopped smoking for at least 3 months or more)
- No history of Drug or Alcohol abuse
If you meet the criteria for this study and would like more information, register below or call 1800 727 874.